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observed after coarctation repair is not a new
phenomenon, but is simply the continuation
of the neurosympathetic process that existed
before the coarctation repair.
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Reply to the Editor:
Robicsek outlined in his letter to the Editor
in response to our article1 that arterial hyper-
tension exists distal the coarctation even
before coarctation repair. Hypertension in
the long-term follow-up is simply the con-
tinuation of this neurosympathetic process.
Previously published data from our
group2 on blood pressure and aortic disten-
sibility in neonates with coarctation before
and after surgical repair did not show
poststenotic hypertension before repair in
general. However, we totally agree with
Robicsek and other authors3,4 that inborn
processes not touched by current modes of
repair are also responsible for hypertension
in the long-term follow-up after successful
repair. We believe that the starting point of
the pathophysiologic chain is the inborn
alteration of the arterial wall with elastic fi-
ber fragmentation, fibrosis, and cystic me-
dial necrosis, which are later exaggerated
by existing hypertension. This causes the in-
creased stiffness most pronounced in the
central elastic arteries, the blunted barore-
ceptor reflex, and the neurosympathetic acti-
vation. However, the novelty of our study
was the extent of this phenomenon. Our
relation to age showed that arterial hyperten-
sion has to be expected in almost all patients
after coarctation repair in older ages. Close
surveillance and aggressive treatment of
arterial hypertension might prevent further
cardiovascular disease.
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To the Editor:
In their article focusing on in vivo autolo-
gous recellularization of a tissue-engineered
heart valve, Vincentelli and colleagues1
raise 2 main questions: (1) Which are the
best candidates for scaffold repopulation?
(2) Does direct injection of cells into the
scaffold guarantee adequate cellular recolo-
nization?
According to the cell type chosen for
scaffold seeding, the adoption of nonse-
lected bone marrow–derived mononuclear
cells was associated with early degeneration
with thickening and retraction of the cusps,
growth of fibrotic pannus along the suture
lines, and thickening and calcification of
the wall conduits. Histologically, a marked
inflammatory response with extracellular
matrix disarray and macrophage infiltration
both in the adventitia and the media layers
were observed, along with a loss of the
proper collagen allocation between thevascular Surgery c June 2008ventricularis, spongiosa, and fibrosa of the
leaflets. Additionally, a significant increase
of both transvalvular and distal gradients
were recorded at 4-month follow-up echo-
cardiographic analysis. On the contrary,
scaffolds repopulated with mesenchymal
stem cells did not evidence either degenera-
tive notes or inflammatory reactions.
These findings might suggest ‘‘the onset
of a structural deterioration of the scaffold in
the [bone marrow–derived mononuclear
cell] group and a protective effect of the
injections of [mesenchymal stem cells].’’1
We are concerned that such conclusions
seem audacious because the study suffers
from a main limitation represented by the
cell-seeding modality. In fact, the authors,
looking for an answer to question number
2, choose to inject the cells directly into
the decellularized scaffold (onto the conduit
walls and valve annulus, excluding the
leaflets), instead of adopting a biomimetic
environment.
The adoption of this alternative tech-
nique,which has been derived from themyo-
cardial setting,2 represents an innovative
concept for the valvular field and therefore
requires a careful validation. Fluorescent
cell tracking, which was performed on 4 of
14 animals in the first postoperative week,
evidenced, on day 1, the cell persistence
onto the injection site and, on day 7, a few
scattered cells into the matrix, the arterial
wall, and the leaflets. Moreover, nonlabeled
cells of host origin were found.
Is this enough to say that ‘‘in situ injec-
tion of bone marrow cells into a porcine
decellularized scaffold before implantation
enhanced the in vivo recolonization and
induced full re-endothelization’’?1 First,
endothelialization and scaffold repopulation
do not coincide. Even bioprostheses un-
dergo an endothelialization process of the
inert components once implanted. Second,
the process of repopulation implies an
architectural and hierarchic cell-specific
distribution along the leaflet’s ventricularis,
spongiosa, and fibrosa,3 which was not
observed in this experience.
In the article’s ‘‘Discussion’’ section, the
authors themselves affirm that they had no
direct evidence that cells would grow inside
the matrix. According to the hypothesis that
injected cells might enhance autologous
recellularization, further evidence is needed
to draw definite conclusions, and the pro-
vided results do not concretely support the
initial hypothesis.
also endothelial cells. Similarly, we observed
a significant recolonization after injection of
MSCs, and moreover, as stated in our arti-
cle, pulmonary leaflets exhibited a typical
organization in 3 layers (ie, fibrosa, spon-
giosa, and ventricularis) in each animal of
the MSC group.2
Finally, several lines of evidence indi-
cate that in vivo recellularization of valve
scaffolds is no longer a ‘‘nonvalidated
route.’’ In a previous work we demon-
strated evidence of spontaneous recellulari-
zation of a decellularized valve.3 Such
results were emphasized by Dohmen and
coworkers4 comparing in vitro seeded and
nonseeded valves implanted in sheep. After
6 months, valves from both groups ex-
hibited full recolonization of the leaflets,
with comparable hemodynamic behavior
and valve remodeling.
We recognize that further studies are
needed to compare spontaneous recoloniza-
tion of an appropriated scaffold and the ef-
fects of in situ injection of autologous cells.
Also, we have to investigate how injected
autologous MSCs improve in situ recoloni-
zation by myofibroblasts and endothelial
valve as a scaffold for in vivo recellularization:
deleterious effects of granulocyte colony-
stimulating factor. J Thorac Cardiovasc Surg.
2006;131:843-52.
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Percutaneous aortic valve
replacement with the CoreValve
bioprosthesis
To the Editor:
We read with interest the recent article by
Marcheix and colleagues1 in the Journal
dealing with percutaneous aortic valve im-
plantation. They reported their experience
using the second generation (21F) of the
CoreValve prosthesis (CoreValve, Inc, Paris,
France) in 10 consecutive high-risk surgical
patients (median logistic EuroSCORE of
32%). The prosthesis was successfully deliv-
ered in all cases, with a doubling of the aortic
valve area (from 0.57 6 0.19 to 1.2 6 0.35
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We thank Drs Di Marco and Gerosa for con-
sidering that injection of mesenchymal stem
cells (MSCs) in decellularized scaffolds be-
fore in vivo implantation represents an inno-
vative concept in the valvular field, and we
completely agree that this concept requires
a careful validation. However, they ex-
pressed some concern about our conclusion
that bone marrow–derived mononuclear cell
injection induced a structural deterioration
of the scaffold and that MSCs induced a pro-
tective effect.
We believe that the observation of a del-
eterious effect of bone marrow–derived
mononuclear cells is an interesting point
because these cells had never been tested
in the field of valve tissue engineering,
whereas they are currently used in clinical
assays in the field of myocardial failure.
Also, we agree that endothelialization and
scaffold recolonization are 2 distinct pro-
cesses that do not always take place
together. However, Bertiplaglia and col-
leagues1 have demonstrated that 2 weeks
after in vitro interstitial cell seeding into
decellularized leaflets, grafted cells were
found penetrating the decellularized scaf-
fold and expressed various immunologic
differentiation patterns, such as fibroblasts,
myofibroblasts, smooth muscle cells, and
cells or improve host cell migration. How-
ever, the challenge seems now to understand
and to favor in vivo, rather than in vitro,
valve scaffold recolonization.
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We would like to comment on these re-
sults and also ask for some clarifications
regarding their data:
Prosthesis sizing is an important issue.
On one hand, undersizing may be responsi-
ble for valve migration (owing to poor
anchoring), perivalvular leak, or patient–
prosthesis mismatch. On the other hand,
oversizing may theoretically lead to coro-
nary obstruction or favor atrioventricular
block. There is actually only one available
size of the CoreValve prosthesis, with
a 21-mm bioprosthesis implanted within
the stent frame. This valve is at the present
time indicated when the aortic annulus
diameter ranges from 20 to 27 mm.2 Al-
though the authors did not report the annu-
lus size in their group of patients, we do
not understand how proper sizing could be
achieved with a single-sized bioprosthesis.
Aortic bicuspidy is observed in half of
cases of severe aortic stenosis.3 In our expe-
rience, misdeployment of a valved stent is
likely to occur within a bicuspid aortic
valve,4,5 which may alter its long-term dura-
bility. Did the authors face a case with
a bicuspid aortic valve or have they system-
atically preoperatively screened the patients
and excluded for the endovascular proce-
dure those with a bicuspid aortic valve?
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